Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.
about
Expression and functional analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 isozymesCytochrome P4502C9: an enzyme of major importance in human drug metabolismEffect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarinFrequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoinWarfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsGenetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans.The future prospects of pharmacogenetics in oral anticoagulation therapy.Quantitative assessment of the effect of cytochrome P450 2C9 gene polymorphism and colorectal cancerGenetics of warfarin sensitivity in an emergency department population with thromboembolic.Genetic predisposition to acute gastrointestinal bleeding after NSAIDs useGenetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: colon cancer family registry.Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy.Warfarin toxicity and individual variability-clinical case.A review and assessment of potential sources of ethnic differences in drug responsiveness.Clinical relevance of genetic polymorphisms in the human CYP2C9 gene.Association of warfarin dose with genes involved in its action and metabolism.The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivatorDifferences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoformsPharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy.Personalized approach of medication by indirect anticoagulants tailored to the patient-Russian context: what are the prospects?The human intestinal cytochrome P450 "pie".Contribution of CYP2C9 to variability in vitamin K antagonist metabolism.Pharmacogenetics of warfarin: current status and future challenges.Novel CYP2C9 promoter variants and assessment of their impact on gene expression.Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarinsDecreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism.Drug interactions with antiretrovirals and warfarin.A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.Expanding role of pharmacogenomics in the management of cardiovascular disorders.Pharmacogenetic biomarkers for predicting drug response.CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.Adherence and variability in warfarin dose requirements: assessment in a prospective cohort.Substrate proton to heme distances in CYP2C9 allelic variants and alterations by the heterotropic activator, dapsone.High allele frequency of CYP2C9*3 (rs1057910) in a Negrito's subtribe population in Malaysia; Aboriginal people of Jahai.Genetic Polymorphism of Cytochrome p450 (2C9) Enzyme in Iranian Baluch Ethnic GroupSelective filling of nanowells in nanowell arrays fabricated using polystyrene nanosphere lithography with cytochrome P450 enzymes.
P2860
Q24320062-0B0D83BC-B43D-4886-AB78-4ED699D504D3Q24683497-7127E35D-551A-45AB-9385-64491D7E67A1Q28276514-2BA2C827-F1FB-4A17-B6FC-57E2BBB47837Q28343618-11D675CA-E283-401B-A163-D445D35C1B34Q28395337-2F04302F-4A28-495B-A61E-FC19152E1E3FQ33538523-D9775C60-19B8-4810-8D77-DE538C7090FAQ33644101-C0290268-584A-4C06-9B70-F7D2B979B428Q34530230-30100139-A4BB-40D2-BDB6-2B07BBB6D0F8Q34663842-AA9388C3-260F-4E9A-9698-1D82DD70812CQ34934523-7A864170-9378-40AE-8DA7-6752837B4C03Q35046080-E665833F-F067-4900-9A59-D8559E7C5A8BQ35078297-6DE44600-A51F-418C-BBAD-256ABD03633CQ35127790-692FF99A-659B-467E-951B-EE5233A31115Q35155651-80325FF0-D881-468F-B3B3-7AB9B01207F4Q35217493-19CAA57A-B300-4030-994A-9F274B144348Q35594567-972AD602-8346-4870-8243-89DCE6D91BE5Q35633802-CE515A27-88CD-4A97-9C74-416FC569DB0FQ35803966-8DB8A1F8-A226-4BC0-8377-ECCE00DB4CC4Q35846894-12734861-BAD6-45E0-A531-B1A36E6EB9A5Q35876954-52D778B3-296F-44CA-B4FE-30AEC77648B5Q36055300-11E04182-6943-4EFB-9F99-A763E4C35265Q36326202-51F9A556-6669-4F65-9F7F-AF425CDB3D72Q36380430-DE30EEC8-372D-4507-895D-859C024E30B8Q36420382-C31FD14C-CC7B-4273-B3DF-4A7671C72FEFQ36545011-48BF4C0E-E404-4199-941E-F2C0FC7E77A7Q36597343-8CCA3C45-6583-4E94-BA01-D6C43EE10BB2Q36699888-01D0022F-C456-4EAF-BCEB-0AD16136E992Q37019459-60EB861E-F95B-4446-B2A5-8C8B6863315DQ37429282-F73206C2-B8AC-4636-9726-1FF9005637C6Q37679935-8787E041-9885-4C29-B14F-CBF8A0FCA0C4Q37908891-F95AB609-7C68-4645-BA44-349B916631BBQ38078754-ABBC6CE2-2BB0-4C61-9302-E3DB0DA88E4CQ38098452-A372CD09-F94F-4506-96C9-7613D1F2C21BQ38214388-1D568C1C-4FD3-4C11-AFFB-C99AC24B1001Q38830008-9E800B59-F98B-4814-9673-BE459B1A8F33Q39483670-E8D6EF4A-EFA2-4ECB-B0EA-1B512A4650C1Q40371454-73F0A2A0-E2AA-471A-8CC8-B6373E192316Q40506725-D4DF8C9C-61F0-4BAA-BD96-019E6A7F7306Q41096175-A2EC28E3-7F8D-49C3-AA1D-9813E435E568Q42499852-8FBED9D4-A8A1-42F1-A15C-FAEDCCA600A5
P2860
Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Allelic variants of human cyto ...... d-type and I359L mutant forms.
@en
Allelic variants of human cyto ...... d-type and I359L mutant forms.
@nl
type
label
Allelic variants of human cyto ...... d-type and I359L mutant forms.
@en
Allelic variants of human cyto ...... d-type and I359L mutant forms.
@nl
prefLabel
Allelic variants of human cyto ...... d-type and I359L mutant forms.
@en
Allelic variants of human cyto ...... d-type and I359L mutant forms.
@nl
P2093
P356
P1476
Allelic variants of human cyto ...... ld-type and I359L mutant forms
@en
P2093
Haining RL
Veronese ME
P304
P356
10.1006/ABBI.1996.0414
P407
P577
1996-09-01T00:00:00Z